Nucleic Acid Nanostructure Vaccines for Controlled Antigen Spacing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating a protective vaccine against HIV-1 is challenging due to the high mutability of the virus and inefficient neutralization of antibodies generated by natural infection or vaccination with native HIV Envelope trimers, necessitating the development of immunization strategies that can effectively elicit broadly neutralizing antibodies (bnAbs) through controlled antigen organization and T cell help.
Innovation Solution
Designing nucleic acid nanostructures with precise control over antigen organization, spacing, and T cell help to enhance germinal center responses, using DNA origami nanoparticles to display immunostimulatory agents like eOD-GT8, incorporating synthetic T cell helper epitopes, and stabilizing agents to minimize B cell competition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native HIV Envelope trimers are used for vaccination, then the vaccine formulation is simple, but the neutralization efficiency is insufficient and broadly neutralizing antibodies cannot be effectively elicited
Solution Approach 1:
The patent segments the vaccine formulation into distinct functional components: nucleic acid nanostructures displaying specific antigenic epitopes (eOD-GT8, eOD-GT12) are separated from T cell helper epitopes (PADRE). This segmentation allows independent optimization of B cell activation through antigen display and T cell help through the PADRE epitope, thereby improving neutralization efficiency without creating an undifferentiated complex formulation
Solution Approach 2:
The patent employs composite nucleic acid nanostructures that combine multiple functional elements: antigenic epitopes (eOD-GT8, eOD-GT12), T cell helper epitopes (PADRE), and adjuvants (TLR agonists). These composite structures integrate B cell activation, T cell help, and immune stimulation into a single coordinated platform, improving neutralization efficiency while maintaining formulation manageability through modular design
2Reliability
If antigen valency is increased to elevate serum responses, then humoral immunity is strengthened, but the nanoparticle design becomes more complex with multiple constraints
Solution Approach 1:
The patent systematically varies key parameters of the nucleic acid nanostructures including antigen density (number of eOD-GT8/eOD-GT12 copies), inter-antigen spacing, nanoparticle size, and T cell help dosage (PADRE epitope inclusion). By optimizing these parameters independently through controlled nucleic acid assembly, the patent achieves enhanced humoral immunity without requiring complex multi-constraint nanoparticle designs
Solution Approach 2:
The nucleic acid nanostructure platform serves multiple functions simultaneously: it displays antigenic epitopes for B cell recognition, provides T cell helper epitopes for T cell activation, incorporates adjuvants for immune stimulation, and controls antigen spacing for optimal immune response. This multi-functionality within a single platform strengthens humoral immunity while avoiding the need for separate complex nanoparticle systems for each function
3Adaptability or versatility
If protein nanoparticles are used to study antigen organization, then in vivo effects can be assessed, but further alterations to nanoparticle symmetry, diameter, antigen spacing, or scaffold-intrinsic T cell help occur
Solution Approach 1:
The patent uses nucleic acid nanostructures as an intermediary platform between in vitro antigen organization studies and in vivo vaccine assessment. The nucleic acid scaffold serves as a controllable mediator that allows precise antigen spacing and arrangement to be established in vitro, then translated to in vivo applications without requiring further alterations to symmetry, diameter, or scaffold-intrinsic T cell help properties
Solution Approach 2:
The patent creates simplified copies of the essential functional elements needed for immune response: nucleic acid nanostructures that replicate the antigen display and T cell help functions without requiring the full complexity of protein nanoparticle systems. These copied functions maintain antigen organization control while eliminating the need for further alterations to nanoparticle properties
Data Source
AI summary
Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and/or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and/or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and/or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and/or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.